<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aflibercept, a recombinant fusion protein, is a potent inhibitor of vascular endothelial growth factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF) </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in combination with <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, levofolinate, and irinotecan (FOLFIRI) in patients with previously treated <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed to assess the safety, dose-limiting toxicities (DLTs), pharmacokinetics, and preliminary efficacy of the combination therapy to determine the recommended phase II dose (RPTD) for Japanese patients </plain></SENT>
<SENT sid="3" pm="."><plain>Two doses of aflibercept (2.0 and 4.0 mg/kg) were set, and DLTs were evaluated in the first 2 cycles </plain></SENT>
<SENT sid="4" pm="."><plain>The subjects comprised 16 patients (n = 3 and 13 for 2.0 and 4.0 mg/kg aflibercept, respectively) who received a total of 149 cycles of aflibercept with FOLFIRI </plain></SENT>
<SENT sid="5" pm="."><plain>No DLTs were observed at both doses </plain></SENT>
<SENT sid="6" pm="."><plain>The frequent adverse events encountered were <z:hpo ids='HP_0001882'>leukopenia</z:hpo>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp>, decreased appetite, <z:hpo ids='HP_0010280'>stomatitis</z:hpo>, <z:hpo ids='HP_0001618'>dysphonia</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, and <z:hpo ids='HP_0000421'>epistaxis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The most common grade 3/4 adverse events were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> for both doses and <z:hpo ids='HP_0000822'>hypertension</z:hpo> for the 4.0 mg/kg dose </plain></SENT>
<SENT sid="8" pm="."><plain>Free aflibercept exposure increased with the dose, whereas exposure to VEGF-bound aflibercept remained similar at both doses </plain></SENT>
<SENT sid="9" pm="."><plain>The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, the combination of aflibercept and FOLFIRI was well tolerated at both doses </plain></SENT>
<SENT sid="11" pm="."><plain>The RPTD of aflibercept in combination with FOLFIRI for Japanese patients with mCRC was determined to be 4.0 mg/kg every 2 weeks </plain></SENT>
<SENT sid="12" pm="."><plain>ClinicalTrials.gov identifier: NCT00921661 </plain></SENT>
</text></document>